Physiologic Pharmacokinetic Modeling of Polychlorinated Biphenyls

Conference paper
Part of the Environmental Toxin Series book series (TOXIN SERIES, volume 1)


A flow-limited physiologic pharmacokinetic model is presented for the analysis of the distribution and disposition of some polychlorinated biphenyl congeners in several animal species. Analysis of the pharmacokinetic parameters in the model gives insight into congener-to-congener and species-to-species comparisons. For example, the partition coefficient for parent compound of all congeners is greatest in the fat tissue. Clearance of PCBs occurs predominantly as metabolites into the urine and feces. Rates of metabolism vary considerable among congeners in all species studied, and there is no apparent scaling factor, such as body weight or surface area, for predicting rates of metabolism from species to species. Physiologic pharmacokinetic models are useful didactic tools for assessing models of distribution of PCBs.


Blood Flow Rate Physiologic Model Chlorinate Biphenyl Didactic Tool Biphenyl Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hutzinger O, Choudry GG, Chittim BG, Johnston LE (1985) Formation of polychlorinated dibenzofurans and dioxins during combustion, electrical equipment fires and PCB incineration. In: Environmental Health Perspectives 60: 3Google Scholar
  2. 2.
    McConnell EE (1985) Comparative toxicity of PCBs and related compounds in various species of animals. In: Environmental Health Perspectives 60: 29Google Scholar
  3. 3.
    Allen JR, Carstens LA, Abrahamson LJ (1976) Response of rats exposed to polychlorinated biphenyl for fifty-two weeks. I. Comparison of tissue levels of PCB and biological changes. In: Arch. Environ. Contam. Toxicol. 4: 404Google Scholar
  4. 4.
    Greenberg L, Mayers MR, Smither AR (1939) The systemic effects resulting from exposure to certain chlorinated hydrocarbons. In: J. Ind. Hyg. Toxicol. 21: 29Google Scholar
  5. 5.
    Alvares AP, Fishbein A, Anderson KE, Kappas A (1977) Alterations in drug metabolism in workers exposed to polychlorinated biphenyls. In: Clinical Pharmacol. and Therapeut. 22: 140Google Scholar
  6. 6.
    Fishbein L (1974) Toxicology of chlorinated biphenyls. In: Ann. Rev. Pharmacol. 14: 139Google Scholar
  7. 7.
    Chen HSG, Gross JF (1979) Physiologically based pharmacokinetic models for anticancer drugs. In: Cancer Chemother. Pharmacol. 2: 85Google Scholar
  8. 8.
    Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: Principles and applications. In: J. Pharm. Sci. 72: 1103Google Scholar
  9. 9.
    Dedrick RL (1973) Animal scale up. In: J. Pharmacokin. Biopharm. 1: 435Google Scholar
  10. 10.
    Dedrick RL, Bischoff KB (1980) Species similarities in pharmacokinetics. In: Federation Proc. 39: 54Google Scholar
  11. 11.
    Lutz RJ, Dedrick RL, Zaharko DS (1980) Physiological pharmacokinetics: An In Vivo Approach to Membrane Transport. In: Pharmac. Ther. 11: 559Google Scholar
  12. 12.
    Lutz RJ, Dedrick RL, Matthews HB, Eling TE, Anderson MW (1977) A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat. In: Drug Metab. Dispos. 5: 386Google Scholar
  13. 13.
    Tuey DB, Matthews HB (1980) Use of a physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. In: Drug Metab. Dispos. 8: 397Google Scholar
  14. 14.
    Anderson MW, Eling TE, Lutz RJ, Dedrick RL, Matthews HB (1977) The construction of a pharmacokinetic model for the disposition of polychlorinated biphenyls in the rat. In: Clin. Pharmacol. Therapeutic. 22: 765Google Scholar
  15. 15.
    Sipes IG, Slocumb ML, Perry DF, Carter DE (1980) 4,4’-Dichlorobiphenyl: Distribution, metabolism, and excretion in the dog and monkey. In: Toxicol. Appl. Pharmacol. 55: 554Google Scholar
  16. 16.
    Sipes IG, Slocumb ML, Chen HSG, Carter DE (1982) 2362’3’6’-Hexachlorobiphenyl:Distribution, metabolism, and excretion in the dog and the monkey. In: Toxicol. Appl. Pharmacol. 62: 317Google Scholar
  17. 17.
    Sipes IG, Slocumb ML, Perry DF, Carter DE (1982) 2452’4’5’-Hexachlorobiphenyl: Distribution, metabolism, and excretion in the dog and the monkey. Toxicol. Appl. Pharmacol. 65: 264Google Scholar
  18. 18.
    Matthews HB, Anderson MW (1975) Effect of chlorination on the distribution and excretion of polychlorinated biphenyls. In: Drug Metab. Dispos. 3: 371Google Scholar
  19. 19.
    Matthews HB, Tuey DB (1980) The effect of chlorine position on the distribution and excretion of four hexachlorobiphenyl isomers. In: Toxicol. Appl. Pharmacol. 53: 377Google Scholar
  20. 20.
    Matthews HB, Anderson MW (1975) The distribution of 2452’ 5’-Pentachlorobiphenyl in the rat. In: Drug Metab. Dispos. 3: 211Google Scholar
  21. 21.
    Kato S, McKinney JD, Matthews HB (1980) Metabolism of symmetrical hexachlorobiphenyl isomers in the rat. In: Toxicol. Appl. Pharmacol. 53: 389Google Scholar
  22. 22.
    Kohli KK, Gupta BN, Albro PW, Mukhtar H, McKinney JD (1979) Biochemical effect of pure isomers of hexachlorobiphenyl (HCB): Fatty livers and cell structure. In: Chem.-Biol. Interact. 25: 139Google Scholar
  23. 23.
    Dedrick RL, Forrester DD, Ho DHW (1972) In-vitro — in vivo correlation of drug metabolism — deamination of 1-D-arabinofuranosylcytosine. In: Biochem. Pharmacol. 21: 1Google Scholar
  24. 24.
    Dedrick RL, Forrester DD, Cannon JN, El Dareer SM, Mellett LB (1973) Pharmacokinetics of 1-D-arabinofuranosylcytosine deamination in several species. In: Biochem. Pharmacol. 22: 2405Google Scholar
  25. 25.
    Collins JM, Blake DA, Egner PG (1978) Phenytoin metabolism in the rat-Pharmacokinetic correlation between in-vitro hepatic microsomal enzyme activity in in-vivo elimination kinetics. In: Drug Metab. Dispos. 6: 251Google Scholar
  26. 26.
    Lin JH, Sugiyama Y, Awazu S, Manabu H (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in-vitro as well as on physiological data. In: J. Pharmacokin. Biopharm. 10: 649Google Scholar
  27. 27.
    Schnellman RG, Vickors FEM, Sipes IG (1985) Metabolism and Disposition of Polychlorinated Biphenyls. In: Hodgson E, Bend J, Philips R (eds) Rev. Biochem. Toxicol. No. 7. Elsevier Press, pp 247–282Google Scholar
  28. 28.
    Schnellman RG, Putnam CW, Sipes IG (1983) Metabolism of 22’33’66’-Hexachlorobiphenyl and 22’44’55’-hexachlorobiphenyl by human hepatic microsomes. In: Biochem. Pharmacol. 32: 3233Google Scholar
  29. 29.
    Parry G, Palmer DN, Williams DJ (1976) Ligand partitioning into membranes: Its significance in determining Km and Ks values for cytochrome P-450 and other membrane bound receptor enzymes. FEBS Letters 67: 123CrossRefGoogle Scholar
  30. 30.
    Lutz RJ, Dedrick RL, Tuey D, Sipes IG, Anderson MW, Matthews HB (1984) Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. In: Drug Metab. Dispos. 12: 527Google Scholar
  31. 31.
    Muhlebach S, Bickel MH (1981) Pharmacokinetics in rats of 2452’4’5’-hexachlorobiphenyl, an unmetabolized lipophilic model compound. In: Xenobiotica 11: 249Google Scholar
  32. 32.
    Matthews HB, Tuey DB (1980) The effect of chlorine position on the distribution and excretion of four hexachlorobiphenyl isomers. In: Toxicol. Appl. Pharmacol. 53: 377Google Scholar
  33. 33.
    Morales NM, Tuey DB, Colburn WA, Matthews HB (1979) Pharmacokinetics of multiple oral doses of selected polychlorinated biphenyls in mice. In: Toxicol. Appl. Pharmacol. 48: 397Google Scholar
  34. 34.
    Hansen LG, Welborn ME (1977) Distribution, dilution, and elimination of polychlorinated biphenyl analogs in growing swine. In: J. Pharm. Sci. 66: 497Google Scholar
  35. 35.
    Wyss PA, Muhlebach S, Bickel MH (1982) Pharmacokinetics of 22’44’55’-hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. I. Effects of restricting food intake two weeks after administration of 6-CB. In: Drug Metab. Dispos. 10: 657Google Scholar
  36. 36.
    Berlin M, Gage J, Holm S (1975) Distribution and metabolism of 2452’5’-Pentachlorophenyl. In: Arch. Environ. Health 30: 141Google Scholar
  37. 37.
    Morales NM, Matthews HB (1979) In-vivo binding of 2362’3’6’-Hexachlorobiphenyl and 2452’4’5’-Hexachlorobiphenyl to mouse liver macromolecules. In: Chem.-Biol. Interactions 27: 99Google Scholar
  38. 38.
    King FG, Dedrick RL, Farris FF (1986) Physiological pharmacokinetic modeling of cis-Dichlorodiammineplatinum (II) (DDP) in several species. In: J. Pharmacokin. Biopharm. 14: 131Google Scholar
  39. 39.
    Yoshimura H, Yamamoto H (1975) A novel route of excretion of 2434’-Tetrachlorobiphenyl in rats. In: Bull. Environ. Contam. Toxicol. 13: 681Google Scholar
  40. 40.
    Bungay PM, Dedrick RL, Matthews HB (1981) Enteric transport of chlordecone (kepone) in the rat. In: J. Pharmacokin. Biopharm. 9: 309Google Scholar
  41. 41.
    Smith RL (1973) The excretory function of bile. Chapman and Hall, London, p 35Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  1. 1.Biomedical Engineering and Instrumentation Branch, Division of Research ServicesNational Institutes of HealthBethesdaUSA

Personalised recommendations